复星医药：关于控股子公司获美国FDA药品注册批准的公告

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval for its self-developed biosimilar injection of Dexamethasone (HLX14) in two specifications: 60mg/mL and 120mg/1.7mL [2] Group 1 - The biosimilar product HLX14 has been granted a Biologics License Application (BLA) by the FDA [2]